Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Cottu, Paul; Laurentiis, Michelino De; Marchetti, Paolo; Coltelli, Luigi; Califaretti, Nadia; Debled, Marc; Patil, Shekhar; Evron, Ella; Duhoux, François; Menon-Singh, Lakshmi; Wu, Jiwen; Zhou, Katie; Bofill, Javier Salvador

doi:10.1093/annonc/mdz242.028

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of note, cytologic data was only available in 20% of the LM patients on this study at study entry, limiting interpretation of the leptomeningeal burden of disease. Currently, there are no published case reports of the efficacy of ribociclib or palbociclib in LM, despite reports of intracranial activity for parenchymal metastases [ 167 – 169 ]. However, the CSF concentration of ribociclib in a phase 0 glioblastoma study at the time of surgery was equal to 0.374 μmol/L, with a CSF-to-plasma unbound ratio of 1.8 (0.6–4.4) [ 170 ].…”

Section: Small Molecule Inhibitorsmentioning

confidence: 99%

Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases

Wilcox

Boire²

2022

CNS Drugs

View full text Add to dashboard Cite

Leptomeningeal metastases represent an aggressive stage of cancer with few durable treatment options. Improved understanding of cancer biology, neoplastic reliance on oncogenic driver mutations, and complex immune system interactions have resulted in an explosion in cancer-directed therapy in the last two decades to include small molecule inhibitors and immune checkpoint inhibitors. Most of these therapeutics are underexplored in patients with leptomeningeal metastases, limiting extrapolation of extracranial and even intracranial efficacy outcomes to the unique leptomeningeal space. Further confounding our interpretation of drug activity in the leptomeninges is an incomplete understanding of drug penetration through the blood-cerebrospinal fluid barrier of the choroid plexus. Nevertheless, a number of retrospective studies and promising prospective trials provide evidence of leptomeningeal activity of several small molecule and immune checkpoint inhibitors and underscore potential areas of further therapeutic development for patients harboring leptomeningeal disease.

show abstract

Section: Small Molecule Inhibitorsmentioning

confidence: 99%

Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases

Wilcox

Boire²

2022

CNS Drugs

View full text Add to dashboard Cite

show abstract

“…Ribociclib combined with letrozole, presented positive results in the CompLEEment-1 study, a phase IIIb trial including HR-positive/HER2-negative MBC patients, with an ORR of 20.5% [ 108 ], and patients from this study with CNS metastases presented favorable results, with an ORR of 41.2% [ 109 ].…”

Section: Systemic Therapies For Bcbmmentioning

confidence: 99%

Advances in the Management of Central Nervous System Metastases from Breast Cancer

Avila

Leone

2022

IJMS

View full text Add to dashboard Cite

Central nervous system (CNS) metastases are common in breast cancer (BC) patients and are particularly relevant as new treatments for BC are prolonging survival. Here, we review advances in the treatment of CNS metastases from BC, including radiotherapy, systemic therapies, and the evolving role of immunotherapy. The use of radiotherapy and chemotherapy is the cornerstone of treatment for CNS metastases. However, new targeted therapies have recently been developed, including anti-HER2 agents and antibody–drug conjugates that have presented promising results for the treatment of these patients.

show abstract

“…Удлинение QT-интервала было редким в обеих группах. Таким образом, профиль безопасности терапии рибоциклибом при наличии метастазов в головной мозг идентичен таковому в общей группе пациенток; частота развития НЯ (включая серьезные и фатальные) была схожа в обеих группах [31].…”

Section: анализ ня в исследовании Compleement-1 (Iiib фазы)unclassified

Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021

2021

J. Mod. Onco.

View full text Add to dashboard Cite

Increasing life expectancy and maintaining its quality are the main goals of the hormone-dependent HER2-negative advanced breast cancer (HR+ HER2- аBC) therapy. A Satellite Symposium of Novartis Pharma was held on January 28th, 2021, within the framework of the RUSSCO Big Conference Breast Cancer. It was dedicated to the benefits of Risarg (ribociclib) therapy in combination with hormone therapy (HT). Experts-oncologists shared current data and their experience with ribociclib. The combination of CDK4/6 inhibitors with HT became a gold standard for the 1st line therapy for HR+ HER2- aBC. And the choice of a specific drug is based on the data of clinical studies and is made taking into account the individual characteristics of the patient. The results of ribociclib studies (MONALEESA-3 and MONALEESA-7) demonstrate a significant increase in the median overall survival and a decrease in the risk of death by 28 and 30%. The tolerance profile of ribociclib is well studied and controlled, therefore the risks of adverse events can be reduced by the competent monitoring, and the necessary dose modification can be made, which allows most patients to maintain highly effective therapy. The use of ribociclib allows to achieve the main goals of therapy to prolong the patients life and maintain or improve its quality.

show abstract

Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Cited by 4 publications

References 0 publications

Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases

Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases

Advances in the Management of Central Nervous System Metastases from Breast Cancer

Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021

Contact Info

Product

Resources

About